易布鲁替尼可调节黑色素瘤细胞中的增殖,迁移,线粒体恒常和亡
Fernanda Vitelli Lins1,2, Elizabete Cristina Iseke Bispo1, Naomí Souza Rodrigues1
1Laboratório de Hematologia e Células-Tronco, Faculdade de Ciências da Saúde, Universidade de Brasília, Brasília 70910-900, DF, Brazil.
Biomedicines
|May 25, 2024
概括
易布鲁替尼有效地通过诱导亡和损害线粒体功能来杀死黑色素瘤细胞. 这种氨酸激酶抑制剂也显示出抗转移的潜力,表明其作为黑色素瘤治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 易布鲁替尼是用于治疗各种癌症的氨酸激酶抑制剂.
- 黑色素瘤仍然是一个重要的健康问题,需要新的治疗策略.
研究的目的:
- 为了研究易布鲁替尼在黑色素瘤细胞系上的抗癌作用.
- 阐明易布鲁替尼在黑色素瘤中的作用背后的机制.
- 评估易布鲁替尼在黑色素瘤中的抗转移潜力.
主要方法:
- 细胞毒性通过MTT测定进行评估.
- 细胞亡,线粒体潜力,ROS,增殖和细胞周期通过流动细胞计分析.
- 基因表达,LDH释放,Caspase 3/7活性和细胞迁移分别通过实时PCR,色度/发光测试和伤口划伤测试进行评估.
主要成果:
- 易布鲁替尼对MeWo,SK-MEL-28和WM164黑色素瘤细胞表现出细胞毒性.
- 细胞亡,通过Annexin V/PI染色,增加的Caspase 3/7活性和LDH释放来证明,是细胞死亡的主要机制.
- 易布鲁替尼治疗降低了线粒体膜潜力,并上调了亲细胞亡基因 (ATM,HRK,BAX,BAK,CASP3,CASP8).
- 易布鲁替尼抑制了黑色素瘤细胞迁移,表明了抗转移效应.
- 基因实体学分析在黑色素瘤样本中将易布鲁替尼的点与亡和亡途径联系起来.
结论:
- 易布鲁替尼会诱导亡并损害黑色素瘤细胞中的线粒体功能.
- 易布鲁替尼具有与黑色素瘤治疗相关的抗转移性质.
- 易布鲁替尼在黑色素瘤治疗中显示出显著的治疗潜力.
相关概念视频
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
01:17Intracellular Signaling Affects Focal Adhesions
2.7K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K